- Home
- OP vs CERO Comparison
OP vs CERO Comparison
Compare OP & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- CERO
- Stock Information
- Founded
- OP 2021
- CERO 2017
- Country
- OP Greece
- CERO United States
- Employees
- OP N/A
- CERO N/A
- Industry
- OP
- CERO
- Sector
- OP
- CERO
- Exchange
- OP Nasdaq
- CERO Nasdaq
- Market Cap
- OP 10.5M
- CERO 8.5M
- IPO Year
- OP N/A
- CERO N/A
- Fundamental
- Price
- OP $1.12
- CERO $0.06
- Analyst Decision
- OP
- CERO
- Analyst Count
- OP 0
- CERO 0
- Target Price
- OP N/A
- CERO N/A
- AVG Volume (30 Days)
- OP 19.7K
- CERO 33.3M
- Earning Date
- OP 12-24-2024
- CERO 11-19-2024
- Dividend Yield
- OP N/A
- CERO N/A
- EPS Growth
- OP N/A
- CERO N/A
- EPS
- OP N/A
- CERO N/A
- Revenue
- OP $22,098,000.00
- CERO N/A
- Revenue This Year
- OP N/A
- CERO N/A
- Revenue Next Year
- OP N/A
- CERO N/A
- P/E Ratio
- OP N/A
- CERO N/A
- Revenue Growth
- OP 9.82
- CERO N/A
- 52 Week Low
- OP $1.04
- CERO $0.05
- 52 Week High
- OP $3.15
- CERO $12.80
- Technical
- Relative Strength Index (RSI)
- OP 23.21
- CERO 39.14
- Support Level
- OP $1.40
- CERO $0.05
- Resistance Level
- OP $1.50
- CERO $0.21
- Average True Range (ATR)
- OP 0.04
- CERO 0.02
- MACD
- OP -0.01
- CERO -0.01
- Stochastic Oscillator
- OP 0.00
- CERO 14.60
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.